Summary
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent financing.
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BG Bart Gancher Intech Investment Management LLC | 21,851 | $145,899.02 | $381,092.37 | $235,193.35 | 161.2% |
 Joseph Castro Nuveen LLC | 188,182 | $1.25M | $3.3M | $2.05M | 163.61% |
| SRB Steve R. Bailey Frazier Life Sciences Management LP | 9.94M | $24.92M | $174.29M | $149.37M | 599.36% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 18 | $335.34 | $323.46 | -$11.88 | -3.54% |
| RO Regan O'Neill Burkehill Global Management LP | 525,000 | $2.87M | $9.44M | $6.57M | 228.66% |
Trevi Therapeutics Inc. (TRVI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Trevi Therapeutics Inc. ever had a stock split?
Trevi Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jennifer L. Good CEO | NASDAQ (NMS) Exchange | 89532M101 CUSIP |
| US Country | 34 Employees | - Last Dividend | - Last Split | 7 May 2019 IPO Date |
Overview
Trevi Therapeutics, Inc. is a New Haven, Connecticut-based clinical-stage biopharmaceutical company dedicated to the advancement of innovative treatments for serious neurologically mediated conditions. With a focus on the development and commercialization of their lead product candidate, Haduvio, Trevi Therapeutics is pushing the boundaries of what is possible in the realm of neurologically based treatments. The company was formed in 2011 and has since been on a mission to bring relief to patients suffering from chronic conditions that are currently underserved by the medical community. Through rigorous research and clinical trials, Trevi Therapeutics aims to unlock new potential in the fight against challenging medical conditions, bolstered by a strategic license agreement with Endo Pharmaceuticals Inc.
Products and Services
- Haduvio (Oral Extended-release Nalbuphine) - This is Trevi Therapeutics' leading product candidate, currently undergoing extensive Phase IIb/III clinical trials to assess its efficacy and safety. Below are the primary areas of focus for Haduvio’s application:
- Chronic Pruritus: Pruritus, or intense itching, is a debilitating condition often associated with various underlying diseases. Haduvio is being developed to address this relentless itching, particularly when it becomes chronic and severely impacts the quality of life of patients.
- Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients: IPF is a fatal disease characterized by scarring of the lungs, leading to a progressive decline in lung function. Treatment options are limited, and the symptom of chronic cough significantly reduces patients' quality of life. Haduvio offers hope as a potential treatment to alleviate this distressing symptom.
